IGF-1 LR3 news and clinical trials
Also known as: Long R3 IGF-I · LR3IGF-I · IGF LR3 · Long Arg3 IGF-1
Updated 20 sources
1 new study in the last 12 months, newest first: trial registrations and results, PubMed papers, FDA actions and press coverage that name IGF-1 LR3. Each line links to the primary source.
July 2026
- StudyPubMedThe emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration (opens PubMed)
A review of peptides modulating the GH-IGF-1 axis highlights the significant gap between clinical evidence and unregulated self-administration protocols. Clinicians are advised to recognize potential adverse effects like endocrine disturbances, fluid retention, and metabolic issues.
Frontiers in endocrinologyReviewPMID 42395176
Searched as: IGF-1 LR3, Long R3 IGF-I, LR3IGF-I, IGF LR3, Long Arg3 IGF-1. Summaries are one or two sentences, published only when every number in them appears in the source record. A tracker, not medical advice.